The test analysis over 2000 changes in BRCA genes and other 17 genes commonly associated with breast, ovarian and endometrial cancer risk. Scientific data demonstrates that sequencing a wider panel of genes offers the advantage of obtaining clinically valuable information.
Pathogenic variants were detected twice more frequently in patients who benefited from multi-gene sequencing than those who had opted for BRCA1 and BRCA2 alone. These pathogenic variants appeared in a variety of genes, including CHEK2, ATM, PALB2, APC, BRIP1, PMS2 and RAD51C.
The result you receive may help you make a medical plan to reduce the risk for breast, ovarian and endometrial cancer.
Ask your doctor for a BRCA Extended Test or order it directly with us
Take the saliva sample according to the instructions in the collection kit and call us for the sample to reach us
Receive the results 3-4 weeks after saliva collection
Elaborate a healthcare plan with your doctor
In the test report you will find the following:
• Clear information on the genetic risk for breast, ovarian and endometrial cancer
• Personalized risk information for ovarian, endometrial and breast cancer
• How you and your doctor can use this information to develop a healthcare plan
The risk to women
A BRCA1mutation may increase the risk of developing breast cancer to 81% and the risk of developing ovarian cancer by up to 54% by the age of 80.
A BRCA2mutation may increase the risk of breast cancer by up to 74% and the risk of developing ovarian cancer by up to 12% by the age of 70.
Extended genetic screening in breast cancer patients increases the rate of detection of variants that cause the disease, which could lead to a change in the healthcare plan, compared to BRCA1 and BRCA2 limited testing.
The risk to men
BRCA1 and BRCA2 gene mutations may increase the risk of breast cancer, melanoma and prostate cancer in men.
Men are also equally likely to have BRCA1 and BRCA2 mutations as well as women and can pass it on to their children.